^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Undisclosed MSC-derived Exosomes with KrasG12D siRNA

    i
    Other names: Undisclosed MSC-derived Exosomes with KrasG12D siRNA, mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA, KrasG12D siRNA-loaded Mesenchymal Stromal Cells-derived Exosomes
    Associations

    News

    Trials
    Company:
    UT MD Anderson Cancer Center
    Drug class:
    KRAS G12D inhibitor, Small interfering RNA inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    NCI-2018-01441: iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=28 --> 15 | Trial completion date: Jun 2023 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Apr 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Stroma • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Undisclosed MSC-derived Exosomes with KrasG12D siRNA
    over1year
    NCI-2018-01441: iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation (clinicaltrials.gov)
    P1, N=28, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
    Trial completion date • Trial primary completion date • Stroma • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Undisclosed MSC-derived Exosomes with KrasG12D siRNA
    over2years
    NCI-2018-01441: iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation (clinicaltrials.gov)
    P1, N=28, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Undisclosed MSC-derived Exosomes with KrasG12D siRNA
    over3years
    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation (clinicaltrials.gov)
    P1; Not yet recruiting --> Recruiting
    Enrollment open • Clinical
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    FoundationOne® CDx
    |
    Undisclosed MSC-derived Exosomes with KrasG12D siRNA